Supportive care for the prevention of nausea, vomiting and anorexia in a phase 1B study of selinexor in advanced cancer patients: an exploratory study-Reference-Cited by-同舟云学术

Supportive care for the prevention of nausea, vomiting and anorexia in a phase 1B study of selinexor in advanced cancer patients: an exploratory study

Published:2021-09-24 Issue:1 Volume:40 Page:124-133
ISSN:0167-6997
Container-title:Investigational New Drugs
language:en
Short-container-title:Invest New Drugs

Author:

Dev Rony^ORCID,Zhong Linda L.,Zarifa Abdulrazzak,Albittar Aya A.,Rubin Laura,Liu Suyu,Yap Timothy A.,Dalal Shalini,Hui David,Karp Daniel D.,Tsimberidou Apostolia M.,Piha-Paul Sarina A.,Ahnert Jordi Rodon,Fu Siqing,Meric-Bernstam Funda,Naing Aung

Publisher

Springer Science and Business Media LLC

Subject

Pharmacology (medical),Pharmacology,Oncology

Link

https://link.springer.com/content/pdf/10.1007/s10637-021-01184-5.pdf

Reference39 articles.

1. Ng TL, Hutton B, Clemons M (2015) Chemotherapy-Induced Nausea and Vomiting: Time for More Emphasis on Nausea? Oncologist 20:576–583

2. Berger MJ, Ettinger DS, Aston J et al (2017) NCCN Guidelines Insights: Antiemesis, Version 2.2017. J Natl Compr Canc Netw 15:883–893

3. Drug Utilization Review Team (DURTO) (2003) Antiemetic prescriptions in Italian breast cancer patients submitted to adjuvant chemotherapy. Support Care Cancer 11:785–789

4. Fearon K, Strasser F, Anker SD (2011) Definition and classification of cancer cachexia; an international consensus. Lancet Oncol 12:489–495

5. Fearon KC, Baracos VE (2010) Cachexia in pancreatic cancer: new treatment option and measure of success. HPB (Oxford) 12:323–324

Cited by 5 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Safety and Preliminary Efficacy of Once-Weekly Split-Dose Selinexor in Soft Tissue Sarcoma: Results of the Phase Ib METSSAR Clinical Trial;Targeted Oncology;2024-06-19

2. Anamorelin for the Treatment of Cancer Anorexia-Cachexia Syndrome;Current Oncology Reports;2024-05-21

3. Phase 1b study of combined selinexor and eribulin for the treatment of advanced solid tumors and triple‐negative breast cancer;Cancer;2023-04-04

4. Olanzapine;Reactions Weekly;2022-11-19

5. The efficacy of selinexor (KPT-330), an XPO1 inhibitor, on non-hematologic cancers: a comprehensive review;Journal of Cancer Research and Clinical Oncology;2022-08-08